Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 3;16(1):33.
doi: 10.1186/s13045-023-01428-2.

PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation

Affiliations

PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation

Andrea Marranci et al. J Hematol Oncol. .

Abstract

In human cells BRAF oncogene is invariably expressed as a mix of two coding transcripts: BRAF-ref and BRAF-X1. These two mRNA isoforms, remarkably different in the sequence and length of their 3'UTRs, are potentially involved in distinct post-transcriptional regulatory circuits. Herein, we identify PARP1 among the mRNA Binding Proteins that specifically target the X1 3'UTR in melanoma cells. Mechanistically, PARP1 Zinc Finger domain down-regulates BRAF expression at the translational level. As a consequence, it exerts a negative impact on MAPK pathway, and sensitizes melanoma cells to BRAF and MEK inhibitors, both in vitro and in vivo. In summary, our study unveils PARP1 as a negative regulator of the highly oncogenic MAPK pathway in melanoma, through the modulation of BRAF-X1 expression.

Keywords: BRAF-X1; MAPK pathway; Melanoma; PARP1; Vemurafenib; mRBP.

PubMed Disclaimer

Conflict of interest statement

None to declare.

Figures

Fig. 1
Fig. 1
PARP1 directly binds the 3′UTR of BRAF-X1 mRNA and negatively regulates its translation in melanoma cells. a REMSA. On the top, schematic representation of the radiolabeled riboprobes used for the experiment. On the bottom, band shifts obtained incubating S100 cytoplasmic protein extract obtained from A375 cells with probe R7 and R8 (blue asterisks). See Additional file 2: Fig. S3 for further details. b Summary of the analytic workflow to which we subjected the 87 cytoplasmic proteins obtained by mass spectrometry analysis of R8 pull-down. c Interaction network of the 51 proteins showing no peptides in pull-down control samples, as obtained by STRING analysis. The 51 proteins are represented as nodes of the network, with the 20 mRBPs highlighted in red. The connections among nodes are depicted as lines and their strength as colors: light gray/gray/black corresponds to 0.5 (weak)/0.75 (intermediate)/1 (strong) overall score. Nodes have been arranged according to the number of connections they have with the other nodes of the network. The lower is the number of connections, the more peripheral is the position of a node. The Protein–Protein Interaction (PPI) enrichment p-value of the network is < 1.0E − 16. d Binding affinity of the 20 mRBPs to the R8 fragment of X1 3′UTR, according to catRAPID omics v2.0 program. RNA Fragment of R8: part of the R8 fragment bound by the mRBP. Interaction Propensity: probability of interaction between one protein (or region) and one RNA (or region). Z_score: correction of potential biases originating from the length of the RNAs and impacting the Interaction Propensity. RBP Propensity: measure of the propensity of the protein to bind the RNA (1 if the protein is in the RBP precompiled library). RNA Binding Domains: number of RNA binding domain occurrences found in the protein sequence. RNA Binding Motifs: number of RNA binding motif instances found on the RNA sequence. Conserved Interactions: number of organisms in which the interaction is conserved out of those in which an orthologous pair is found. Ranking: the ranking results from three individual values: (1) catRAPID corrected propensity, (2) RBP propensity, and (3) presence of known RNA Binding Motifs. The 5 top-scoring protein are reported. PARP1 has the highest rank, DHX36 is fourth, while STRAP is 17th (complete list in Additional file 6: Table S4). e Pull-down assay reveals the direct binding between desthiobiotinylated R8 riboprobe and recombinant PARP1 protein. Both the unrelated 3′UTR of Androgen Receptor mRNA, provided by the pull-down kit, and R2 riboprobe, which does not show any band shift when incubated with S100 cytoplasmic protein extract of A375 cells (see also Additional file 1), were used as negative controls. f Luciferase assays in A375 cells. The full-length ref or X1 3ʹUTR, as well as the X1 3′UTR missing the R8 region (X1 ΔR8, left) were cloned downstream of Luciferase CDS in pMIR plasmid, so that pMIR-ref-3′UTR, pMIR-X1-3′UTR and pMIR-X1-3′UTRΔR8 Luciferase plasmids were obtained. Such plasmids were either cotransfected with siCT/siPARP1 in A375 cells (middle), or transfected in A375 cells previously infected with pCW-CTRL/pCW-PARP1 vectors (right). 48 h after transfection, PARP1 knock-down is associated with an increase in the Luciferase activity of pMIR-X1-3′UTR plasmid, but not of pMIR-ref-3′UTR and pMIR-X1-3′UTRΔR8 plasmids, indicating that PARP1 interacts specifically with the X1 3′UTR, and more precisely with the R8 region. Consistently, 48 h after transfection and concomitant induction with 2ug/ml of doxycycline, PARP1 overexpression results in a decrease in the Luciferase activity of pMIR-X1-3′UTR plasmid. g Western blot analysis of BRAF protein level in A375 and 501Mel cells. Western blot was performed 48 h after the transfection of siPARP1 (left), or 48 h after induction of PARP1 overexpression in cells stably infected with pCW-PARP1 vector and treated with 2ug/ml doxycycline (right). A representative western blot result (top) and bands quantification (bottom) are shown. h The RTE of pMIR-X1-3′UTR plasmid, which is the ratio between Luciferase protein activity and Luciferase mRNA level, was calculated in A375 cells, 48 h after the cotransfection of the Luciferase plasmids with siPARP1. Graphs represent the mean ± SEM of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. i BRAF mRNA expression (RSEM) in the group of high PARP1 protein expressors (25% percentile) versus low PARP1 protein expressors (75% percentile) within the TCGA-SKCM melanoma patient dataset. j BRAF protein expression (RPPA) in the group of high PARP1 protein expressors (25% percentile) versus low PARP1 protein expressors (75% percentile) within the TCGA-SKCM melanoma patient dataset
Fig. 2
Fig. 2
PARP1 Zn domain is responsible for the negative regulation of BRAF-X1 translation, and inhibits MAPK pathway in vitro and in vivo. a Schematic representation of the functional domains of PARP1 protein (3042 bp, 1014 aa): DNA/RNA Binding domain, which in turn is composed of 3 Zinc Finger motifs (Zn, green); Auto-modification domain (Auto, gray); Catalytic (parylating) domain (Cat, blue). b Luciferase assay in A375 cells. Among the functional domains tested (pCW-HA-Zn (green), pCW-HA-Auto (gray) and pCW-HA-Cat (blue)), only the overexpression of the Zn domain recapitulates the decrease in Luciferase activity of pMIR-X1-3′UTR plasmid, as observed with full length pCW-PARP1 (orange). The assay was performed 48 h after the transfection of the Luciferase plasmids in cells stably infected with the indicated pCW(-HA) vectors, and the induction of protein overexpression with 2ug/ml doxycycline. c Western blot analysis of BRAF protein level in A375 cells stably infected with pCW-CTRL, pCW-HA-Zn, pCW-HA-Auto, pCW-HA-Cat and pCW-PARP1 vectors, 48 h after induction with 2ug/ml doxycycline. A representative western blot result (left) and bands quantification (right) are shown. d The RTE of pMIR-X1-3′UTR plasmid was calculated in A375 cells stably infected with pCW-CTRL or pCW-HA-Zn, 48 h after transfection of Luciferase plasmids and induction with 2ug/ml doxycycline. e Structural model of PARP1 domain in complex with R8 RNA fragment. PARP1 is represented as surface, while R8 is represented as cartoon. The Zn domain (residues 1–353) is green, the Auto-modification domain (residues 389–643) is gray and the Catalytic domain (residues 662–1014) is blue. The other residues that do not belong to one of these three domains are purple. R8 phosphate-deoxyribose backbone is cyan, while the color code for nitrogenous bases is as follows: A red; G light green; C yellow; U light blue. f RIP-qRT-PCR assay. A375 cells, stably infected with pCW-CTRL or pCW-HA-Zn, were subjected to RIP-qRT-PCR 48 h after induction with 2ug/ml doxycycline. RIP was performed with anti-HA-tag sepharose beads and was coupled with qRT-PCR quantification of BRAF-ref and BRAF-X1 mRNA. g Western blot analysis of BRAF and its downstream effector pMEK in A375 cells stably infected with pCW-CTRL or pCW-HA-Zn, 48 h after induction with 2ug/ml doxycycline. A representative western blot result (left) and bands quantification (right) are shown. h Proliferation assay of A375 and 501Mel cells stably infected with pCW-CTRL or pCW-HA-Zn, 7 days after induction with 2ug/ml doxycycline. i Wound closure assay of A375 cells stably infected with pCW-CTRL or pCW-HA-Zn, 48 h after induction with 2ug/ml doxycycline. j Representative pictures (top), size (bottom left) and distance from injection site (bottom right) of metastases developed in a xenograft model in zebrafish embryos. A375 cells, stably infected with pCW-CTRL or pCW-HA-Zn, were resuspended in PBS and were injected in 48hpf embryos. Then, embryos were allowed to grow for 96 h in E3 medium supplemented with 2ug/ml doxycycline. At the end of this period, the size of red cell masses and their distance from injection site were measured. Scale bar: 300um. k Percentage of γ-H2AX positive cells. γ-H2AX foci, which mark DNA damage, were stained in A375 cells stably infected with pCW-CTRL or pCW-HA-Zn, 48 h after induction with 2ug/ml doxycycline. pCW-CTRL infected cells were concomitantly treated with the indicated concentrations of Olaparib. See Additional file 2: Fig. S21 for representative pictures of each experimental condition. l Total ROS levels measured in A375 cells stably infected with pCW-CTRL, pCW-HA-Zn or pCW-PARP1, after 48 h of induction with 2ug/ml doxycycline and concomitant treatment with 2uM vem. m Growth curve of A375 cells stably infected with pCW-CTRL, pCW-HA-Zn or pCW-PARP1, after 7 days of induction with 2ug/ml doxycycline and concomitant treatment with the indicated concentrations of vem. n Proliferation assay of A375 cells stably infected with pCW-CTRL, pCW-HA-Zn or pCW-PARP1, 14 days after induction with 2ug/ml doxycycline and treatment with the indicated concentrations of vem, cob or vem + cob. o Area of tumors developed in a xenograft model in zebrafish embryos. A375 cells, stably infected with pCW-CTRL or pCW-HA-Zn, were injected in 48hpf embryos. Then, embryos were allowed to grow for 48 h in E3 medium supplemented with 2ug/ml doxycycline and 2uM vem. At the end of this period, the area of red cell masses was quantified. Representative pictures (left) and the results of area quantification (right) are shown. Scale bar: 300um. Graphs represent the mean ± SEM of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. p Cartoon summarizing our findings. PARP1 is a new player in the regulation of the highly oncogenic MAPK pathway in melanoma. Through the mRNA binding activity of its Zn domain, it negatively regulates the translation of BRAF-X1 isoform, leading to a decrease in MAPK signaling and, consequently, a decrease in cell proliferation/motility accompanied by an increase in sensitivity to MAPKi. Cartoon created with BioRender.com

References

    1. Erson-Bensan AE. RNA-biology ruling cancer progression? Focus on 3′UTRs and splicing. Cancer Metastasis Rev. 2020;39:887–901. doi: 10.1007/s10555-020-09884-9. - DOI - PubMed
    1. Marranci A, Jiang Z, Vitiello M, Guzzolino E, Comelli L, Sarti S, et al. The landscape of BRAF transcript and protein variants in human cancer. Mol Cancer. 2017;16:66. doi: 10.1186/s12943-017-0645-4. - DOI - PMC - PubMed
    1. Lubrano S, Comelli L, Piccirilli C, Marranci A, Dapporto F, Tantillo E, et al. Development of a yeast-based system to identify new hBRAFV600E functional interactors. Oncogene. 2019;38:66. doi: 10.1038/s41388-018-0496-5. - DOI - PubMed
    1. Marranci A, D’Aurizio R, Vencken S, Mero S, Guzzolino E, Rizzo M, et al. Systematic evaluation of the microRNAome through miR-CATCHv2.0 identifies positive and negative regulators of BRAF-X1 mRNA. RNA Biol. 2019;16:66. doi: 10.1080/15476286.2019.1600934. - DOI - PMC - PubMed
    1. Bitaraf A, Razmara E, Bakhshinejad B, Yousefi H, Vatanmakanian M, Garshasbi M, et al. The oncogenic and tumor suppressive roles of RNA-binding proteins in human cancers. J Cell Physiol. 2021;236:6200–6224. doi: 10.1002/jcp.30311. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources